Expertise in
8
conditions

Dr. Barbara A. Burtness

Oncology | Interventional Cardiology
Yale University
20 York St, 
New Haven, CT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Burtness is an Oncologist and an Interventional Cardiologist in New Haven, Connecticut. Dr. Burtness is highly rated in 8 conditions, according to our data. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, and Anaplastic Thyroid Cancer.

Her clinical research consists of co-authoring 212 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Interventional Cardiology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Berzosertib, Cisplatin
Study Phase: Phase 1
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: April 03, 2023
Intervention Type: Drug
Study Drugs: CDX-3379, Cetuximab
Study Phase: Phase 2
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer
Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug
Study Drug: 5-Azacitadine
Study Phase: Phase 1
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Unknown
Publish Date: October 26, 2021
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
View 10 Less Clinical Trials

209 Total Publications

AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancers.
AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancers.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Similar Doctors
Expertise in
49
conditions
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology
Expertise in
49
conditions
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hari Deshpande is an Interventional Cardiologist and an Oncologist in New Haven, Connecticut. Dr. Deshpande is highly rated in 49 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Gastrostomy.

Expertise in
16
conditions
Dr. Scott N. Gettinger
Oncology | Hematology
Expertise in
16
conditions
Dr. Scott N. Gettinger
Oncology | Hematology

Yale University

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4191
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist and a Hematologist in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Francine M. Foss
Expertise in
21
conditions
Dr. Francine M. Foss
Oncology
Expertise in
21
conditions
Dr. Francine M. Foss
Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-2433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francine Foss is an Oncologist in New Haven, Connecticut. Dr. Foss is highly rated in 21 conditions, according to our data. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burtness's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile